Response defined as a PP-NRS ≥4-point improvement from baseline. At week 1 of ARCADIA 1, 19.5% of patients experienced significant itch relief vs 7.5% with placebo. Consistent results seen in ARCADIA 2. At Week 1 of OLYMPIA 2, 32.2% of patients experienced significant itch relief vs 6.6% with placebo. Consistent results were seen in OLYMPIA 1.6
In a post-hoc, observed-case analysis of responders at Week 16 of the OLYMPIA pivotal trials who entered the LTE (N=90), 82% experienced PP-NRS 0/1 at Week 148 of the OLYMPIA LTE. No conclusions regarding efficacy should be made based on these results.7
In a post-hoc, observed-case analysis of responders at Week 16 of the ARCADIA pivotal trials who entered the LTE (N=295), 81% experienced SCORAD Pruritus VAS 0/1 at Week 152 of the ARCADIA LTE. No conclusions regarding efficacy should be made based on these results.7
Deep skin healing defined as IGA 0 or PAS item 5b (100%) in PN and IGA 0 or EASI 90 in AD. Data based on post-hoc, observed-case analysis, at Week 152 of the ARCADIA LTE and Week 148 of the OLYMPIA LTE of responders who achieved primary endpoint responses at Week 16 of the pivotal trials. No conclusions regarding efficacy should be made based on these results.7
~90%
commercial coverage; first-line preferred brand without a biologic OR JAK STEP7

Co-Pay Assistance
Qualified, commercially insured patients with a prescription may pay as little as $0 for NEMLUVIO and can be automatically re‑enrolled for the following year if they are still on the same treatment.
Sign up now for more information
about NEMLUVIO for AD and PN
MOA=mechanism of action; PP-NRS=Peak Pruritus Numerical Rating Scale; Q4W=every 4 weeks; TCI=topical calcineurin inhibitor; TCS=topical corticosteroid.
References: 1. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P. 2. Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. Front Med (Lausanne). 2021;8:639097. doi:10.3389/fmed.2021.639097 3. Liu D, Del Duca E, Delaleu N, et al. Tape strip transcriptomics reveal nemolizumab effects on pruritus, hyperplasia, inflammation, and extracellular matrix markers in patients with moderate-to-severe atopic dermatitis. Allergy. 2026. doi:10.1111/all.70505 4. Patrick MT, Wu Y, Zhong X, et al. IL31 identified as a key genetic risk factor for prurigo nodularis. J Allergy Clin Immunol. 2025;156(5):1410-1413. doi:10.1016/j.jaci.2025.06.031 5. Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2014;133(2):448-460. doi:10.1016/j.jaci.2013.10.048 6. Ständer S, Elmariah SB, Kwatra SG, et al. Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies. J Eur Acad Dermatol Venereol. 2025;00:1‑9. doi:10.1111/jdv.70250 7. Galderma Laboratories, L.P.; data on file.